8
Jun

New chemotherapy approach offers breast cancer patients a better quality of life

The chemotherapy drug capecitabine gives patients a better quality of life and is as effective at preventing breast cancer from returning as the alternative regimen called CMF, when given following epirubicin. These are the results of a clinical trial part-funded by Cancer Research UK (link is external) and published* in The Lancet Oncology today (Tuesday).

Around 4,400 patients** on the TACT2 clinical trial were treated with the chemotherapy drug epirubicin followed by either capecitabine or CMF, after surgery.

Read Full Article Here >>